Evidence map›Paper›PMID 35588334›Full record

ArticleCellular and molecular life sciences : CMLS2022

Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway.

Ying Cao, Weili Mai, Rui Li, Shuwei Deng, Lan Li, Yanxi Zhou, Qiushi Qin, Yue Zhang, Xingang Zhou, Ming Han and 6 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. [Protective effect of knock-down the expression ofBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 2 countries.

Ying Cao *Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Weili Mai *Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Rui Li *Beijing Institute of Infectious Diseases, Beijing, 100015, China.
Shuwei DengBeijing Institute of Infectious Diseases, Beijing, 100015, China.
Lan LiBeijing Institute of Infectious Diseases, Beijing, 100015, China.
Yanxi ZhouBeijing Institute of Infectious Diseases, Beijing, 100015, China.
Qiushi QinBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Yue ZhangBeijing Institute of Infectious Diseases, Beijing, 100015, China.
Xingang ZhouDepartment of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Ming HanBeijing Institute of Infectious Diseases, Beijing, 100015, China.
Pu LiangBeijing Institute of Infectious Diseases, Beijing, 100015, China.
Yonghong YanBeijing Institute of Infectious Diseases, Beijing, 100015, China.
Yu HaoBeijing Institute of Infectious Diseases, Beijing, 100015, China.
Wen XieCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. xiewen6218@163.com.
Jie YanCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. jieyan@ccmu.edu.cn.
Liuluan ZhuBeijing Institute of Infectious Diseases, Beijing, 100015, China. zhuliuluan@ccmu.edu.cn.ORCID http://orcid.org/0000-0001-9078-2576
Capital Medical University · CN

Funding

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support ZYLX201828Beijing Municipal Excellent Talents Foundation 2018000021223ZK27National Natural Science Foundation of China 81600454National Natural Science Foundation of China 81671940National Natural Science Foundation of China 81770577National Natural Science Foundation of China 81871586
6 · The paper itself

Abstract

The pathogenesis of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) remains unclear and the effective treatments have not been explored yet. The activation of hepatic stellate cells (HSCs) is considered as the most critical factor in the progression of liver fibrosis and cirrhosis. Autophagy has recently been identified as a new mechanism to regulate HSC activation. Here, we found that liver macrophages were polarized toward type 2 (M2) during the progression of nonalcoholic steatohepatitis (NASH) and liver fibrosis in both patients and NAFLD mice. Using the methionine-choline-deficient (MCD) diet NAFLD murine model and the in vitro cell culture system, we identified that the M2 macrophages promoted HSC autophagy by secreting prostaglandin E2 (PGE2) and binding its receptor EP4 on the surface of HSCs, which consequently enhanced HSC activation, extracellular matrix deposition, and liver fibrosis. Mechanistically, PGE2/EP4 signals enhanced HSC autophagy through the Erk pathway. A specific PGE2/EP4 antagonist E7046 significantly inhibited M2 macrophage-mediated HSC autophagy and improved liver fibrosis and histopathology in NAFLD mice. Our study provides novel mechanistic insights into the regulation of HSC activation and liver fibrosis. Our findings suggest that the PGE2/EP4 pathway is a promising therapeutic target to prevent NASH progression into cirrhosis.

Indexed as

Hepatic Stellate CellsNon-alcoholic Fatty Liver DiseaseAnimalsAutophagyBenzoatesDinoprostoneFibrosisHumansLiverLiver CirrhosisMacrophagesMiceMice, Inbred C57BLPyrazolesBenzoatesDinoprostoneE7046PyrazolesAutophagyE7046Erk1/2Macrophage polarizationType 2 macrophage

Identifiers

PMID35588334
PMCPMC11071853
OpenAlexW4280541808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.